ifosfamide has been researched along with Acute Confusional Senile Dementia in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " At present, MB is the first line of treatment in methemoglobinemias, is used frequently in the treatment of ifosfamide-induced encephalopathy, and is routinely employed as a diagnostic tool in surgical procedures." | 4.87 | Cellular and molecular actions of Methylene Blue in the nervous system. ( Hasan, M; Lorke, DE; Oz, M; Petroianu, GA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oz, M | 1 |
| Lorke, DE | 1 |
| Hasan, M | 1 |
| Petroianu, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic[NCT04619290] | Phase 1 | 46 participants (Anticipated) | Interventional | 2020-10-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Cellular and molecular actions of Methylene Blue in the nervous system.
Topics: Alzheimer Disease; Animals; Humans; Ifosfamide; Methemoglobinemia; Methylene Blue; Neurons | 2011 |